Explore
Validate
Learn
Western blot
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [6]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA003575 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA003575, RRID:AB_1080378
- Product name
- Anti-TRIM22
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human TRIM22, Gene description: tripartite motif containing 22, Alternative Gene Names: GPSTAF50, RNF94, STAF50, Validated applications: WB, IHC, ICC, Uniprot ID: Q8IYM9, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.3 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references
A novel
TRIM22
gene polymorphism promotes the response to PegIFNα therapy through cytokine-cytokine receptor interaction signaling pathway in chronic hepatitis B
miR-215 Enhances HCV Replication by Targeting TRIM22 and Inactivating NF-κB Signaling
TRIM5α and TRIM22 Are Differentially Regulated According to HIV-1 Infection Phase and Compartment
Neuroblastoma tumorigenesis is regulated through the Nm23-H1/h-Prune C-terminal interaction
Association of TRIM22 with the Type 1 Interferon Response and Viral Control during Primary HIV-1 Infection
The human IFN-inducible p53 target gene TRIM22 colocalizes with the centrosome independently of cell cycle phase
Wang L, Lin N, Zhang Y, Guo S, Liu C, Lin C, Zeng Y, Wu W, Guo J, Zhu C, Zhan F, Ou Q, Xun Z, Liu W
Microbiology Spectrum 2023;11(6)
Microbiology Spectrum 2023;11(6)
miR-215 Enhances HCV Replication by Targeting TRIM22 and Inactivating NF-κB Signaling
Tian H, He Z
Yonsei Medical Journal 2018;59(4):511
Yonsei Medical Journal 2018;59(4):511
TRIM5α and TRIM22 Are Differentially Regulated According to HIV-1 Infection Phase and Compartment
Singh R, Patel V, Mureithi M, Naranbhai V, Ramsuran D, Tulsi S, Hiramen K, Werner L, Mlisana K, Altfeld M, Luban J, Kasprowicz V, Dheda K, Abdool Karim S, Ndung'u T, Doms R
Journal of Virology 2014;88(8):4291-4303
Journal of Virology 2014;88(8):4291-4303
Neuroblastoma tumorigenesis is regulated through the Nm23-H1/h-Prune C-terminal interaction
Carotenuto M, Pedone E, Diana D, de Antonellis P, Džeroski S, Marino N, Navas L, Di Dato V, Scoppettuolo M, Cimmino F, Correale S, Pirone L, Monti S, Bruder E, Ženko B, Slavkov I, Pastorino F, Ponzoni M, Schulte J, Schramm A, Eggert A, Westermann F, Arrigoni G, Accordi B, Basso G, Saviano M, Fattorusso R, Zollo M
Scientific Reports 2013;3(1)
Scientific Reports 2013;3(1)
Association of TRIM22 with the Type 1 Interferon Response and Viral Control during Primary HIV-1 Infection
Singh R, Gaiha G, Werner L, McKim K, Mlisana K, Luban J, Walker B, Karim S, Brass A, Ndung'u T
Journal of Virology 2011;85(1):208-216
Journal of Virology 2011;85(1):208-216
The human IFN-inducible p53 target gene TRIM22 colocalizes with the centrosome independently of cell cycle phase
Petersson J, Lönnbro P, Herr A, Mörgelin M, Gullberg U, Drott K
Experimental Cell Research 2010;316(4):568-579
Experimental Cell Research 2010;316(4):568-579
No comments: Submit comment
Enhanced validation
- Submitted by
- Atlas Antibodies (provider)
- Enhanced method
- Genetic validation
- Main image
- Experimental details
- Western blot analysis in U-87MG ATCC cells transfected with control siRNA, target specific siRNA probe #1 and #2, using Anti-TRIM22 antibody. Remaining relative intensity is presented. Loading control: Anti-PPIB.
- Sample type
- Human
- Protocol
- Protocol
